Heyholder
‹ Activism Filings

OliX Pharmaceuticals, Inc. Q3 operating loss of KRW 16.3 billion, larger than a year earlier

OliX Pharmaceuticals, Inc.· Periodic Report

AI summary · Not investment advice

Olix sold KRW 2.2 billion in Q3 and lost KRW 16.3 billion from its main business, versus sales of KRW 2.9 billion and a KRW 8.3 billion loss a year earlier.

Operating profit · 3 months

KRW -16.3 billion

Key facts

Revenue (3 months)
KRW 2.2 billion
Net income (3 months)
KRW -12.2 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 2.9 billion
Revenue (year to date)
KRW 8.4 billion
Operating profit (prior-year 3 months)
KRW -8.3 billion
Operating profit (year to date)
KRW -41.1 billion
Net income (prior-year 3 months)
KRW -8.7 billion
Net income (year to date)
KRW -32.9 billion

Commentary

AI commentary · Not investment advice

What happened

Olix reported its consolidated results for the third quarter of 2026 in its quarterly report. Sales for the latest 3 months were KRW 2.16 billion, down 25.7% from the same period a year earlier. Cumulative sales this year are KRW 8.36 billion.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 16.31 billion. A year earlier, the 3-month figure was a loss of KRW 8.31 billion. The cumulative operating loss this year is KRW 41.10 billion.

What changes for shareholders

Net income (final profit after taxes and all other items) for the latest 3 months was a loss of KRW 12.15 billion. A year earlier, the 3-month figure was a loss of KRW 8.66 billion. The cumulative net loss this year is KRW 32.91 billion.

Comments

No comments yet

Comments from shareholders will appear here.